Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Argus Health
Healthtrust
QuintilesIMS
Fish and Richardson
Medtronic
McKesson
Queensland Health
Teva
Baxter

Generated: June 18, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR NEO-MEDROL

« Back to Dashboard

Clinical Trials for NEO-MEDROL

Trial ID Title Status Sponsor Phase Summary
NCT00023231 Pediatric Kidney Transplant Without Calcineurin Inhibitors Completed National Institute of Allergy and Infectious Diseases (NIAID) N/A The purpose of this study is to see the effect of using drugs other than calcineurin inhibitors to improve the rate of kidney transplant failure. Kidney transplantation can help children with end-stage kidney disease. However, it has been difficult to find treatment for donor graft rejection that does not have a lot of side effects. Researchers hope to find treatments (immunosuppressants) with fewer side effects. One approach is to avoid using calcineurin inhibitors and to try a new drug known as sirolimus instead. Another is to use steroids less often. This study will test whether using sirolimus, fewer steroid treatments, MMF, and certain antibodies will improve long-term graft survival in children receiving kidney transplants from living donors.
NCT00104299 Rituximab for the Treatment of Wegener's Granulomatosis and Microscopic Polyangiitis Completed Genentech, Inc. Phase 2/Phase 3 Antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis is the most common type of small blood vessel inflammation in adults. ANCA-associated vasculitis includes Wegener's granulomatosis (WG) and microscopic polyangiitis (MPA). Rituximab is a man-made antibody used to treat certain types of cancer. The purpose of this study is to determine the effectiveness of rituximab in treating patients with WG and MPA. Study hypothesis: Rituximab is not inferior to conventional therapy in its ability to induce disease remission by Month 6.
NCT00104299 Rituximab for the Treatment of Wegener's Granulomatosis and Microscopic Polyangiitis Completed Immune Tolerance Network (ITN) Phase 2/Phase 3 Antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis is the most common type of small blood vessel inflammation in adults. ANCA-associated vasculitis includes Wegener's granulomatosis (WG) and microscopic polyangiitis (MPA). Rituximab is a man-made antibody used to treat certain types of cancer. The purpose of this study is to determine the effectiveness of rituximab in treating patients with WG and MPA. Study hypothesis: Rituximab is not inferior to conventional therapy in its ability to induce disease remission by Month 6.
NCT00104299 Rituximab for the Treatment of Wegener's Granulomatosis and Microscopic Polyangiitis Completed National Institute of Allergy and Infectious Diseases (NIAID) Phase 2/Phase 3 Antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis is the most common type of small blood vessel inflammation in adults. ANCA-associated vasculitis includes Wegener's granulomatosis (WG) and microscopic polyangiitis (MPA). Rituximab is a man-made antibody used to treat certain types of cancer. The purpose of this study is to determine the effectiveness of rituximab in treating patients with WG and MPA. Study hypothesis: Rituximab is not inferior to conventional therapy in its ability to induce disease remission by Month 6.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Clinical Trial Conditions for NEO-MEDROL

Condition Name

Condition Name for NEO-MEDROL
Intervention Trials
Osteoarthrosis 6
Leukemia 5
Graft Versus Host Disease 1
Vasculitis 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for NEO-MEDROL
Intervention Trials
Osteoarthritis 9
Joint Diseases 6
Leukemia 5
Precursor Cell Lymphoblastic Leukemia-Lymphoma 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for NEO-MEDROL

Trials by Country

Trials by Country for NEO-MEDROL
Location Trials
United States 31
Denmark 9
India 3
Netherlands 2
Belgium 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for NEO-MEDROL
Location Trials
Texas 5
New York 3
Maryland 3
Illinois 2
Pennsylvania 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for NEO-MEDROL

Clinical Trial Phase

Clinical Trial Phase for NEO-MEDROL
Clinical Trial Phase Trials
Phase 4 4
Phase 3 8
Phase 2/Phase 3 3
[disabled in preview] 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for NEO-MEDROL
Clinical Trial Phase Trials
Completed 14
Recruiting 10
Unknown status 6
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for NEO-MEDROL

Sponsor Name

Sponsor Name for NEO-MEDROL
Sponsor Trials
Bispebjerg Hospital 7
Rigshospitalet, Denmark 6
M.D. Anderson Cancer Center 5
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for NEO-MEDROL
Sponsor Trials
Other 45
Industry 14
NIH 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Accenture
Chinese Patent Office
US Department of Justice
Teva
Queensland Health
Daiichi Sankyo
Healthtrust
UBS
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.